As of May 25, 2025, Abb Ltd's estimated intrinsic value ranges from $23.10 to $70.00 per share, depending on the valuation methodology applied.
Valuation Method | Fair Value (USD) | Implied Upside/Downside |
---|---|---|
Discounted Cash Flow (10Y) | $51.85 | +10.9% |
Discounted Cash Flow (5Y) | $46.38 | -0.8% |
Dividend Discount Model (Multi-Stage) | $42.85 | -8.4% |
Dividend Discount Model (Stable) | $70.00 | +49.7% |
Earnings Power Value | $23.10 | -50.6% |
Is Abb Ltd (ABBN.SW) undervalued or overvalued?
With the current market price at $46.76, the stock appears to be fairly valued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Abb Ltd's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
WACC Component | Low | High |
---|---|---|
Long-term bond rate | 1.0% | 1.5% |
Equity market risk premium | 5.1% | 6.1% |
Adjusted beta | 0.87 | 0.93 |
Cost of equity | 5.4% | 7.7% |
Cost of debt | 4.0% | 4.5% |
Tax rate | 21.2% | 23.2% |
Debt/Equity ratio | 0.07 | 0.07 |
After-tax WACC | 5.3% | 7.4% |
Our DCF model projects cash flows over 5-year and 10-year horizons, with the following key assumptions:
DCF Model | Fair Value | Enterprise Value | % from Terminal Value |
---|---|---|---|
5-Year Growth | $56 | $108,413M | 85.1% |
10-Year Growth | $63 | $120,807M | 73.4% |
5-Year EBITDA | $28 | $55,651M | 71.0% |
10-Year EBITDA | $35 | $68,751M | 53.3% |
The DDM values a company based on its expected future dividend payments. We used two approaches:
EPV assesses a company's value based on its current normalized earnings power, assuming no growth.
EPV Component | Value |
---|---|
Normalized Earnings | $3,423M |
Discount Rate (WACC) | 7.4% - 5.3% |
Enterprise Value | $46,233M - $65,086M |
Net Debt | $3,326M |
Equity Value | $42,907M - $61,760M |
Outstanding Shares | 1,861M |
Fair Value | $23 - $33 |
Selected Fair Value | $23.10 |
Metric | Value |
---|---|
Market Capitalization | $87002M |
Enterprise Value | $89733M |
Trailing P/E | 25.64 |
Forward P/E | 25.84 |
Trailing EV/EBITDA | 7.70 |
Current Dividend Yield | 80.23% |
Dividend Growth Rate (5Y) | 0.47% |
Debt-to-Equity Ratio | 0.07 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
Valuation Method | Weight | Weighted Value |
---|---|---|
Discounted Cash Flow (10Y) | 30% | $15.56 |
Discounted Cash Flow (5Y) | 25% | $11.60 |
Dividend Discount Model (Multi-Stage) | 20% | $8.57 |
Dividend Discount Model (Stable) | 15% | $10.50 |
Earnings Power Value | 10% | $2.31 |
Weighted Average | 100% | $48.53 |
Based on our comprehensive valuation analysis, Abb Ltd's weighted average intrinsic value is $48.53, which is approximately 3.8% above the current market price of $46.76.
Key investment considerations:
Given these factors, we believe Abb Ltd is currently fairly valued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.